Traws Pharma (TRAW) Competitors $1.85 -0.03 (-1.60%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$1.88 +0.02 (+1.35%) As of 09/26/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. CELU, ALGS, ARTV, CUE, ALXO, RLMD, GNTA, PDSB, KPTI, and ICCCShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Celularity (CELU), Aligos Therapeutics (ALGS), Artiva Biotherapeutics (ARTV), Cue Biopharma (CUE), ALX Oncology (ALXO), Relmada Therapeutics (RLMD), Genenta Science (GNTA), PDS Biotechnology (PDSB), Karyopharm Therapeutics (KPTI), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Its Competitors Celularity Aligos Therapeutics Artiva Biotherapeutics Cue Biopharma ALX Oncology Relmada Therapeutics Genenta Science PDS Biotechnology Karyopharm Therapeutics ImmuCell Traws Pharma (NASDAQ:TRAW) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Do analysts rate TRAW or CELU? Celularity has a consensus target price of $6.00, indicating a potential upside of 166.67%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Celularity 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TRAW or CELU? In the previous week, Traws Pharma had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for Traws Pharma and 1 mentions for Celularity. Celularity's average media sentiment score of 1.91 beat Traws Pharma's score of 0.95 indicating that Celularity is being referred to more favorably in the news media. Company Overall Sentiment Traws Pharma Positive Celularity Very Positive Do insiders and institutionals believe in TRAW or CELU? 8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 13.6% of Traws Pharma shares are owned by company insiders. Comparatively, 22.1% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, TRAW or CELU? Celularity has higher revenue and earnings than Traws Pharma. Celularity is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$230K56.79-$166.52M$88.830.02Celularity$54.22M1.11-$57.89M-$3.18-0.71 Which has more risk & volatility, TRAW or CELU? Traws Pharma has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Is TRAW or CELU more profitable? Traws Pharma has a net margin of 3,028.25% compared to Celularity's net margin of -165.22%. Celularity's return on equity of -459.57% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma3,028.25% -1,812.48% 512.72% Celularity -165.22%-459.57%-57.71% SummaryCelularity beats Traws Pharma on 9 of the 16 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.28M$2.51B$5.63B$10.32BDividend YieldN/A58.03%5.79%4.65%P/E Ratio0.0223.8175.7526.14Price / Sales56.79518.39526.41121.04Price / CashN/A172.2337.1160.83Price / Book-0.215.1712.416.36Net Income-$166.52M$32.95M$3.29B$270.97M7 Day Performance-8.87%2.40%1.27%0.34%1 Month Performance30.28%5.97%3.43%6.06%1 Year Performance-67.77%-8.14%63.29%27.34% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma1.2153 of 5 stars$1.85-1.6%N/A-69.7%$13.28M$230K0.0217News CoverageCELUCelularity1.8755 of 5 stars$2.15-1.8%$6.00+179.1%-25.0%$58.45M$54.22M-0.68220Positive NewsGap DownALGSAligos Therapeutics3.8554 of 5 stars$8.95-4.5%$50.00+458.7%+22.1%$57.64M$3.94M-0.4590ARTVArtiva Biotherapeutics3.2227 of 5 stars$2.37+0.9%$17.00+617.3%-77.8%$57.40M$250K0.0081Positive NewsCUECue Biopharma2.3871 of 5 stars$0.74+0.4%N/A+56.3%$56.86M$9.29M-1.3360News CoveragePositive NewsALXOALX Oncology3.651 of 5 stars$1.08+2.9%$3.30+205.6%+0.0%$56.23MN/A-0.4940Positive NewsRLMDRelmada Therapeutics2.8902 of 5 stars$1.60-4.2%$1.00-37.5%-44.8%$55.43MN/A-0.7210Positive NewsGNTAGenenta Science2.7915 of 5 stars$3.05+1.3%$25.00+719.9%-22.4%$55.05MN/A0.007Gap UpPDSBPDS Biotechnology1.947 of 5 stars$1.20+3.4%$10.00+733.3%-67.4%$54.55MN/A-1.3020KPTIKaryopharm Therapeutics3.6941 of 5 stars$6.26flat$34.00+443.1%-38.2%$54.28M$145.24M-0.43380ICCCImmuCell1.3735 of 5 stars$5.90-0.8%N/A+67.0%$53.82M$26.49M31.0570Positive NewsGap Down Related Companies and Tools Related Companies Celularity Competitors Aligos Therapeutics Competitors Artiva Biotherapeutics Competitors Cue Biopharma Competitors ALX Oncology Competitors Relmada Therapeutics Competitors Genenta Science Competitors PDS Biotechnology Competitors Karyopharm Therapeutics Competitors ImmuCell Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 9/27/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRAW Stock Alerts